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Abstract
A study conducted by Lai and colleagues, published
this week in BMC Medicine, suggests that more
guidance might be required for interpreting
systematic review (SR) results. In the study by Lai and
colleagues, positive (or favorable) results were
influential in changing participants’ prior beliefs about
the interventions presented in the systematic review.
Other studies have examined the relationship
between favorable systematic review results and the
publication of systematic reviews. An international
registry may decrease the number of unpublished
systematic reviews and will hopefully decrease
redundancy, increase transparency, and increase
collaboration within the SR community. In addition,
using guidance from the Preferred Items for
Systematic Reviews and Meta-analyses (PRISMA:
http://www.prisma-statement.org/) Statement and the
Grading of Recommendations Assessment,
Development, and Evaluation (GRADE: http://www.
gradeworkinggroup.org/) approach can also be used
to improve the interpretation of systematic reviews. In
this commentary, we highlight important
methodological issues related to the conduct and
reporting of systematic reviews and also present our
own guidance on interpreting systematic reviews.
Please see Research article: http://www.biomedcentral.
com/1741-7015/9/30/.
Introduction
In BMC Medicine this week, Lai and colleagues exam-
ined the ability of 95 hospital clinicians, allied health
professionals, laboratory technicians, and 35 medical
students to accurately generate conclusions from four
systematic review (SR) abstracts [1]. SRs are syntheses
of relevant research consisting of a clearly formulated
question and explicit methods to identify, select, criti-
cally appraise, extract, and analyze data (The Cochrane
Handbook: http://www.cochrane.org/training/cochrane-
handbook). A meta-analysis is a statistical technique to
quantitatively integrate the results of included studies
and is not always conducted in a SR. Lai et al. found
that although medical students were better able to deci-
pher the correct conclusion compared to hospital staff,
only 30.1% of participants correctly identified both the
direction of effect and strength of evidence.
A similar study examined the level of agreement
between SR results and reviewers’ conclusion statements
[2]. Two reviewers independently used a categorization
guide to classify SR results and conclusions from a sam-
ple of 296 SRs indexed in MEDLINE in November
2004. Conflicts were resolved by discussion or the invol-
vement of a third reviewer. Only moderate agreement
between SR results and conclusions was observed
(kappa = 0.55; 95% confidence interval: 0.47, 0.64). The
results of these two studies suggest that more guidance
might be required for interpreting SR results. In this
commentary, we highlight important methodological
issues related to the conduct and reporting of SRs and
also present our own guidance on interpreting SRs.
Discussion
Methodological issues related to the conduct and
reporting of systematic reviews
Publication bias occurs when “investigators, reviewers,
and editors submit or accept manuscripts for publication
based on the direction or strength of the study findings”
[3]. The impact of publication bias has been widely
examined for clinical trials [4-8], for which it has been
suggested that studies with statistically positive results
and large effect sizes can exaggerate a treatment’s effec-
tiveness by 20% [9]. These results highlight the impor-
tance of including unpublished studies in SRs. However,
unpublished studies are often difficult to locate, especially
when funded by private industry [10,11]. Clinical trial
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registries were developed to surmount issues related to
publication bias of clinical research, yet challenges to
their use persist [12,13].
In the study by Lai and colleagues, positive (or favor-
able) results were more influential in changing partici-
pants’ prior beliefs about the interventions presented in
the SRs than negative results [1]. Previous studies have
examined the relationship between SR results and the
publication of SRs. In a cross-sectional study of 296 SRs
indexed in MEDLINE, 36.5% of the overall sample had
favorable results [2]. This increased to 57.7% for
Cochrane and 64.3% for non-Cochrane reviews with a
meta-analysis of the primary outcome. In an interna-
tional survey of 348 SR authors, 1,405 published (med-
ian: 2.0, range: 1 to 150) and 199 unpublished (median:
2.0, range: 1 to 33) SRs were reported [14]. Participants
reported that 13 out of 19 of the most recent unpub-
lished SRs for which a meta-analysis was conducted had
favorable results for their primary outcome. In another
study including 93 published Cochrane reviews, the
median time to publication was 1.63 years (range 0.15
to 7.31 years); positive and negative results were not
associated with the time to publication [15].
The PRISMA Statement calls for an international reg-
istry for SR protocols [16], which is currently under
development [17]. An international registry may
decrease the number of unpublished SRs and will hope-
fully decrease redundancy, increase transparency, and
increase collaboration within the SR community.
Guidance on interpreting SR results
In the study by Lai and colleagues, the medical students
received a structured and clinically integrated evidence-
based medicine course, while the hospital practitioners
received an introductory course on evidence-based med-
icine [1]. The medical students were better able to cor-
rectly match the SR abstract with the respective
conclusion statement, suggesting that different forms of
SR training may have a different impact. Their results
imply that systematic reviewers and end users of SRs
may benefit from education on conducting SRs, includ-
ing how to interpret SR results. In addition, enhancing
the format of SRs to make them user-friendly may
improve the interpretation of SR results [18-20]. Exam-
ples of such initiatives include Clinical Evidence (http://
clinicalevidence.bmj.com) and the Program in Policy
Decision-Making (http://www.researchtopolicy.ca/).
Some systematic reviewers include end users of the
review (for example, patients, policy makers, health care
professionals) in the SR process [21] or circulate a draft
of their discussion to their target audience. These efforts
increase the applicability and relevance of SR results and
promote adequate interpretation of the results from the
different stakeholders’ perspectives. Peer review feedback
on the interpretation of SR results can also be sought by
presenting the SR at a conference. Other approaches
include using guidance from the Preferred Items for
Systematic Reviews and Meta-analyses (PRISMA) State-
ment, Grading of Recommendations Assessment, Devel-
opment, and Evaluation (GRADE), and using a
categorization guide to interpret meta-analyses.
The PRISMA Statement provides reporting guidance for
SR authors [16] and suggests that systematic reviewers
should summarize their main SR findings in a balanced
manner, including the strength of evidence for each of the
main outcomes. The results should be put into context by
considering not only their statistical significance, but also
the clinical, political, and resource implications of rele-
vance to patients, healthcare providers, and policy-makers.
Limitations of the included studies should be discussed by
focusing on the risk of bias (or methodological quality)
results. Limitations in the SR process itself should be
noted, which can be assessed using tools for appraising SR
quality (for example, Assessment of Multiple Systematic
Reviews; AMSTAR) [22-24].
GRADE considers four factors in grading the strength of
recommendations; quality, benefit versus harm, values and
preferences, and resources [25,26]. The quality of evidence
is based on study limitations, inconsistency of results,
imprecision, reporting bias, and indirectness of evidence.
GRADE was originally designed for assessing clinical prac-
tice guidelines, yet has gained popularity within the SR
community and is endorsed by The Cochrane Collabora-
tion (The Cochrane Handbook). Limitations of GRADE
include that it requires training, provides limited guidance
for examining non-intervention or non-diagnostic studies,
and requires ‘scientific value judgments’ to be made about
a body of evidence, which is often difficult for non-
experimental research (for example, observational studies,
qualitative studies) [27,28].
If a meta-analysis was conducted, SR authors may also
find it useful to use a categorization guide to interpret
the results [2,9]. Using the example of a SR examining a
particular intervention versus a comparator, favorable
results (that is, statistically significant positive effect in
favor of the intervention with an associated P-value
≤0.05 or a trend towards a positive result that is non-
statistically significant, see Text Box) would be classified
as a positive finding and the authors would recommend
the intervention. If the intervention also had a statisti-
cally significant increase in adverse events then the
authors may recommend the intervention at the discre-
tion of the patient. The authors may not recommend
the intervention if there is a statistically significant
increase in serious adverse events. Unfavorable results
(that is, statistically significant negative effect in favor of
the nonintervention comparator with an associated P-
value ≤0.05 or a trend towards a negative result that is
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non-statistically significant) would be classified as a nega-
tive finding; hence, the authors would advise against the
use of the intervention or not recommend the interven-
tion. A neutral result (that is, effect size between 0.95
and 1.05 and the confidence interval (CI) crosses 1 for
dichotomous outcomes or the CI crosses 0 for continu-
ous outcomes) would be classified as a neutral finding
and the authors would report no evidence supporting or
refuting the intervention’s effectiveness. Indeterminate
results include whether the SR has more than one pri-
mary outcome with different results, the meta-analysis is
based on few studies or patients or the SR results are
likely affected by bias. In these circumstances, the
authors may report insufficient evidence or that more
research is required.
Conclusions
An international registry of systematic review protocols
may decrease the number of unpublished SRs and will
hopefully decrease redundancy, increase transparency,
and increase collaboration within the SR community.
The interpretation of SR results may be improved by
educating systematic reviewers and end users of SRs,
enhancing the format of SRs to make them user-
friendly, and including end users in the entire review
process. Other approaches include using the PRISMA
Statement, GRADE, and a categorization guide for
meta-analysis results. Such efforts will increase the
applicability and relevance of the SR results and may
help to ensure adequate interpretation of the results.
Text box: Meta-analysis
The outcome used in a meta-analysis is determined by
the data obtained from the included studies. Binary (or
event) data can be meta-analyzed using odds ratios, rela-
tive risk, and the risk difference. Continuous data can be
meta-analyzed using the mean difference and standar-
dized mean difference. Other types of outcomes that
can be meta-analyzed include hazard ratios (takes time
into consideration) and correlation coefficients. Two
main types of models used for meta-analysis include the
fixed effects model and the random effects model. The
fixed effects model does not take between-study variabil-
ity into account, while the random effects model does
[29]. Meta-regression is a statistical tool that can be
used to examine how variables of interest are related to
the meta-analysis results [30,31]. Bayesian approaches to
meta-analyses have also been used [32,33]. Further
information on meta-analysis can be found in The
Cochrane Handbook.
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